Evergreen Capital Management’s GSK GSK Stock Holding History

Evergreen Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78M	Buy	33,664 +808	+2%	+$42.7K	0.03%	361
2026 Q1	$1.83M	Buy	32,856 +2,794	+9%	+$151K	0.04%	335
2025 Q4	$1.49M	Buy	30,062 +2,427	+9%	+$113K	0.03%	373
2025 Q3	$1.2M	Buy	27,635 +6,816	+33%	+$266K	0.03%	364
2025 Q2	$806K	Buy	20,819 +10,803	+108%	+$413K	0.02%	415
2025 Q1	$392K	Sell	10,016 -499	-5%	-$18.3K	0.01%	601
2024 Q4	$361K	Sell	10,515 -1,282	-11%	-$46.1K	0.01%	646
2024 Q3	$487K	Sell	11,797 -336	-3%	-$13.7K	0.02%	511
2024 Q2	$472K	Buy	12,133 +564	+5%	+$23.7K	0.02%	482
2024 Q1	$501K	Buy	11,569 +252	+2%	+$10.4K	0.02%	448
2023 Q4	$424K	Buy	11,317 +522	+5%	+$18.7K	0.02%	459
2023 Q3	$395K	Buy	10,795 +451	+4%	+$16K	0.02%	451
2023 Q2	$372K	Buy	10,344 +1,444	+16%	+$51.8K	0.02%	480
2023 Q1	$320K	Buy	8,900 +1,077	+14%	+$37.7K	0.01%	487
2022 Q4	$276K	Buy	+7,823	New	+$261K	0.01%	510
2022 Q3	–	Sell	-7,018	Closed	-$384K	–	625
2022 Q2	$384K	Buy	7,018 +1,544	+28%	+$85.2K	0.02%	375
2022 Q1	$298K	Buy	5,474 +283	+5%	+$15.4K	0.01%	482
2021 Q4	$286K	Buy	5,191 +264	+5%	+$13.7K	0.01%	492
2021 Q3	$235K	Buy	4,927 +168	+4%	+$8.44K	0.01%	499
2021 Q2	$237K	Buy	+4,759	New	+$229K	0.01%	467
2020 Q1	–	Sell	-3,626	Closed	-$213K	–	431
2019 Q4	$213K	Buy	+3,626	New	+$202K	0.02%	428
2018 Q2	–	Sell	-4,191	Closed	-$205K	–	382
2018 Q1	$205K	Buy	+4,191	New	+$195K	0.02%	337

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Evergreen Capital Management's GSK Position: Q2 2026 in Review

Evergreen Capital Management increased its GSK (GSK) stake by 2.5% in Q2 2026, buying an estimated $42.7K and bringing the position to 33,664 shares worth $1.78M. The position accounts for 0.03% of the portfolio, ranked #361.

Evergreen Capital Management first reported a position in GSK in Q1 2018 and has held it in 22 quarters since. The position peaked at $1.83M in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Evergreen Capital Management held 33,664 shares of GSK worth $1.78M as of Q2 2026.
Evergreen Capital Management bought 808 GSK shares in Q2 2026, an estimated $42.7K.
GSK made up 0.03% of Evergreen Capital Management's portfolio in Q2 2026, its #361 holding.
Evergreen Capital Management first reported a position in GSK in Q1 2018 and has held it in 22 quarters since.
Evergreen Capital Management's GSK position peaked at $1.83M in Q1 2026.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.